Investor Presentaiton slide image

Investor Presentaiton

9th largest generic company in France; among top 20 generic companies in Spain Among top 10 in Euro 3 bn French generics market with over 2.5% market share ■ Launched >200 presentations (>90 molecules) in France so far Focusing on expanding market coverage thru new product launches incl. Day 1 opportunities Recognized as one of the most reliable partner to deal with by the pharmacists - a result of continuous focus on enrichment of customer relations Among top 20 in Euro 0.8 bn Spanish market ■ Launched >35 molecules in Spain so far ■ Plan to increase product portfolio to tap less penetrated market Overall, registered sales of Rs. 2,755 Mio. in FY 10-11 in Europe, up by 13% in Euro terms 116 Regulatory pipeline from India 67 21 64 49 46 KEY STRENGTHS Leveraging India's low cost base - started supplying over 35% of France sales from India New product filings include 39 products for Spanish market New Products Site Transfers Filed Approved Launched 11
View entire presentation